Hastina 24+4

Hastina 24+4 is a prescription combined oral contraceptive tablet that contains the synthetic progestogen drospirenone and the estrogen ethinylestradiol, formulated with lactose anhydrous as an inactive ingredient. Marketed in the European Union, the product is intended for oral administration to provide hormonal contraception. It belongs to the drug class of combined oral contraceptives and is for women of reproductive age seeking birth control.

Hastina 24+4 is prescribed as a combined hormonal contraceptive for several gynecological indications.

- Prevention of pregnancy by consistently inhibiting ovulation, thickening cervical mucus, and altering the endometrial lining. - Regulation of menstrual cycles, helping to achieve more predictable bleeding patterns and reduce irregular spotting. - Reduction of moderate acne that can be linked to hormonal fluctuations, offering an additional dermatologic benefit. - Relief of dysmenorrhea and menstrual‑related pelvic pain, often resulting in improved daily comfort during periods. - Management of premenstrual syndrome symptoms such as mood swings, breast tenderness, and bloating, supporting overall well‑being.

Like other combined oral contraceptives, Hastina 24+4 may be associated with a range of side effects that vary in frequency and severity.

Common: - Nausea, occasional vomiting, or mild stomach upset, especially when first starting the tablet. - Headache, including tension‑type or mild migraine, which often improves after several cycles. - Breast tenderness, swelling, or a feeling of fullness that may lessen over time. - Spotting, breakthrough bleeding, or irregular bleeding between scheduled periods, typically decreasing after the first few months.

Serious: - Deep vein thrombosis, pulmonary embolism, or other thromboembolic events, which require immediate medical attention. - Severe hypertension, stroke, myocardial infarction, or other serious cardiovascular complications.

Before prescribing Hastina 24+4, clinicians evaluate several safety considerations to minimize risk and ensure appropriate use.

- Contraindicated in women who are pregnant, breastfeeding, or have a known hypersensitivity to any component. - Not recommended for individuals with a history of thromboembolic disorders, stroke, or myocardial infarction. - Caution in smokers aged 35 years or older due to increased cardiovascular risk. - Use with caution in patients with uncontrolled hypertension, diabetes mellitus, or liver disease. - May affect lipid metabolism; periodic monitoring of cholesterol levels is advisable. - Consider potential interaction with hormonal conditions such as estrogen‑dependent tumors.

Hastina 24+4 can interact with other medicines, which may alter its effectiveness or increase adverse effects.

Avoid: - Concomitant use with potent enzyme inducers such as rifampin, carbamazepine, or phenytoin, which can reduce contraceptive efficacy. - Combined use with other hormonal contraceptives, which may increase the risk of hormonal side effects.

Use with caution: - Antifungal agents like ketoconazole or itraconazole that inhibit CYP3A4, potentially raising hormone levels. - Certain antibiotics (e.g., clarithromycin) that may modestly affect hormone metabolism. - Herbal supplements containing St. John’s Wort, which can decrease plasma concentrations of the active hormones. - Medications that affect fluid balance, such as diuretics, may require blood pressure monitoring.